Aerosol therapy past, present, and future: A clinician's perspective

Respiratory Care

Volumn 45, Issue 6, 2000, Pages 769-776

  Everard, Mark L ^a  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Aerosol; Dry powder inhaler; Metered dose inhaler; Nebulizer

Indexed keywords

RESPIRATORY TRACT AGENT;

AEROSOL; CONFERENCE PAPER; DEVICE; DRUG DELIVERY SYSTEM; HUMAN; INSTRUMENTATION; LUNG DISEASE; TECHNOLOGY;

AEROSOLS; ASTHMA; FORECASTING; HUMANS; LUNG DISEASES; NEBULIZERS AND VAPORIZERS; PATIENT COMPLIANCE;

EID: 0033932275     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Sakula A. A history of asthma: the FitzPatrick Lecture 1987. J R Coll Physicians Lond 1988;22(1):36-44
2. Webb J, Rees J, Clark TJ. A comparison of the effects of different methods of administration of beta-2 sympathomimetics in patients with asthma. Br J Dis Chest 1982;76(4):351-357.
3. Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor control. Lancet 1999;353(9150):364-369.
4. Speizer FE, Doll R, Heaf P. Observations on recent increase in mortality from asthma. Br Med J 1968;1(5588):335-339.
5. Blauw GJ, Westendorp RGJ. Asthma deaths in New Zealand: who-dunnit? (editorial) Lancet 1995;345(8941):2-3
6. Campbell MJ, Cogman GR, Holgate ST, Johnston SL. Age specific trends in asthma mortality in England and Wales. 1983-95: results of an observational study. BMJ 1997;314(7092):1439-1441.
7. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Pocock SJ, Kerrebijn KF. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-Specific Lung Disease Study Group. Am Rev Respir Dis 1992;146(3):547-554.
8. Bisgaard H, Moller H. Changes in risk of hospital readmission among asthmatic children in Denmark, 1978-1993. BMJ 1999;319(7204): 229-230.
9. Laitinen LA, Laitinen A. Mucosal inflammation and bronchial hyperreactivity (review). Eur Respir J 1988;1(5):488-489
10. United States Food and Drug Administration, Division of Pulmonary Drug Products. Class labeling for intranasal and orally inhaled corticosteroid containing drug products, regarding the potential for growth suppression in children. November 9, 1998. http://www.fda.gov/cder/news/cs-label.htm. Accessed May 15, 2000.
11. Lipworth BJ. New perspective on inhaled drug delivery and systemic bioactivity (review). Thorax 1995;50(2):105-110
12. Pedesen S. Inhalers and nebulizers: which to choose and why (review). Respir Med 1996;90(2):69-77.
13. Agertoft L, Pederson S. Final height of asthmatic children treated for 7-11 years with inhaled budesonide (abstract). Am J Respir Crit Care Med 1998;157(4 Pt 2):A711.
14. Paterson IC, Crompton GK. Use of pressurised aerosols by asthmatic patients Br Med J 1976;1(6001):76-77.
15. Thorsson L, Edsbacker S. Lung deposition of budesonide from a pressurised metered-dose inhaler attached to a spacer. Eur Respir J 1998;12(6):1340-1345.
16. Friegang B. New method of beclomethasone aerosol administration to children under 4 years of age. Can Med Assoc J 1977;117(11): 1308-1309.
17. Newman SP, Millar AB, Lennard-Jones TR, Moren F, Clarke SW. Improvement of pressurised aerosol deposition with Nebuhaler spacer device. Thorax 1984;39(12):935-941.
18. Janssens HM, Devadason SG, Hop WCJ, Le Souef PN, De Jongste JC. Tiddens HA. Variability of aerosol delivery via spacer devices in young asthmatic children in daily life Eur Respir J 1999;13(4):787-791.
19. Davies HA, Lennard L, Lilleyman JS. Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance? BMJ 1993;306(6887):1239-1240.
20. Gibson NA, Ferguson AE, Aitchison TC, Paton JY. Compliance with inhaled medication in preschool children. Thorax 1995;50(12): 1274-1279
21. Braunstein GL, Trinquet G, Harper AE. Compliance with nedocromil sodium and a nedocromil sodium/salbutamol combination. Compliance Working Group. Eur Respir J 1996;9(5):893-898.
22. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996;98(6 Pt 1):1051-1057.
23. Armitage JM, Williams SJ Inhaler technique in the elderly. Age Ageing 1988;17(4):275-278
24. Everard ML. Delivering aerosolised drugs to distressed children is a thankless task. Arch Dis Child 2000;82:428
25. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients compliance with prescribed oral and inhaled asthma medications. Arch Int Med 1994;154:349-351.
26. Health literacy: report of the Council of Scientific Affairs Ad Hoc Committee on Health Literacy for the Council of Scientific Affairs. American Medical Association. JAMA 1999:281(6):552-557.
27. Hanania NA, Wittman R, Kesten S, Chapman KR. Medical personnel's knowledge of and ability to use inhaling devices: metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest 1994;105(1):111-116.
28. Everard ML, Dolovich M. In vivo measurements of lung dose. In: Drug delivery to the lung: clinical aspects. Bisgaard H, O'Callaghan C, Smaldone G, editors. (In series 'Lung biology in health and disease'). In press.
29. Goldman JM, Bayston SM, O'Connor S, Meigh RE. Inhaled micronised gencamicin powder, a new delivery system. Thorax 1990, 45(12):939-940.
30. Smith G. A patient's view of cystic fibrosis. J Adolesc Health Care 1986;7(2):134-138